Ti trovi qui: Home » Ricerca » Laboratorio di ricerca

Laboratorio di ricerca

Lab. nameDrug delivery and targeting  
Principal Investigator Valentina Iannuccelli 
ComponentsValentina Iannuccelli  (Principal Investigator )
Eliana Grazia Leo  (Principal Investigator )
Eleonora Truzzi  (Dottorando )
Eleonora Maretti  (Collaboratore )
DescriptionThe Principal Investigator Dr. Valentina Iannuccelli coordinates the research concerning: A) Inhalable lipid carrier for tuberculosis therapy. According to the World Health Organization global tuberculosis (TB) remains one of the world's ambitodeadliest communicable diseases, despite implementation of highly standard treatment regimen that has caused the number of cases began to decline from 1992. The current long therapy, responsible for patient's non-compliance that is the most common reason for treatment failure, is connected to Mycobacterium tuberculosis (Mtb) nature. The urgency to effectively treat tuberculosis (TB) disease may be addressed with the development of new carriers able to deliver existing drugs to the target site in a more efficient way via pulmonary route. Particulate carriers, developed for an acceptable inhaled therapy for lung TB infection, exhibit the possibility to provide both passive and active targeting, using surface engineering approaches, to infected alveolar macrophages (AM) and facilitate cell internalization. For this purpose, our research has been focused for several years on lipid microparticles, in particular on the assembly of Solid Lipid Nanoparticles, as rifampicin carrier for an inhaled anti-TB therapy by DPI devices, so exploiting the use of a proven drug and biomaterials already accepted by regulators. The research avails itself of national and international partnerships. The scientific results achieved over the past decade to date were published in: 1) Maretti E., Rustichelli C., Romagnoli M., Balducci A.G., Buttini F:, Sacchetti F., Leo E:, Iannuccelli V.* (2016). Solid Lipid Nanoparticle assemblies (SLNas) for an anti-TB inhalation treatment-A Design of Experiments approach to investigate the influence of pre-freezing conditions on the powder respirability. INTERNATIONAL JOURNAL OF PHARMACEUTICS (ISSN:0378-5173), 511, 669-679, doi: 10.1016/j.ijpharm.2016.07.062 2) Iannuccelli V.*, Maretti E. (2016). Inhaled micro- or nanoparticles: which are the best for intramacrophagic antiinfectious therapies? JOURNAL OF INFECTIOUS DISEASES AND DIAGNOSIS, 1: e101 3) Maretti E., Rossi T., Bondi M., Croce M.A., Hanuskova M., Leo E., Sacchetti F., Iannuccelli V.* (2014) Inhaled Solid Lipid Microparticles to target alveolar macrophages for tuberculosis INTERNATIONAL JOURNAL OF PHARMACEUTICS, 462, 74-82, ISSN:0378-5173, doi: 10.1016/j.ijpharm.2013.12.034 4) Maretti E., Costantino L., Rustichelli C., Leo E., Croce M.A., Buttini F., Truzzi E., and Iannuccelli V.* Surface engineering of Solid Lipid Nanoparticle assemblies by a mannose derivative for alveolar macrophage active targeting in anti-TB inhalation therapy, submitted B) Skin permeation of bioactive molcules and particulate carriers. The research aims to develop lipid micro- and nanoparticles able to modulate the skin permeation of bioactive molecules. In particular, alternative in vitro methods predicting in vivo percutaneous absorption that represent a challenge to which the researchers are called in order to eliminate or reduce the pharmacological and toxicological tests on animal models, are involved. The research avails itself of national partnerships and the results achieved to date were published in several papers.  
Addressvia Giuseppe Campi, 103 - 41125 Modena 
KeywordsPulmonary drug delivery, Skin permeation, Parenteral drug delivery, Oral drug delivery 
ERC Sectors LS6_11 Prevention and treatment of infection by pathogens (e.g. vaccination, antibiotics, fungicide) LS7_3 Pharmacology, pharmacogenomics, drug discovery and design, drug therapy  
Research Lines Translational Medicine

Web Site www.dsv.unimore.it/site/home/ricerca/gruppi-di-ricerca.html